Clinical trialPhase 2Completed
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
Phase II Trial Evaluating the Safety and Efficacy of Atezolizumab in Combination With Cabozantinib for the Treatment of Metastatic, Refractory Pancreatic Cancer
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 12 October 2021
- Expected end
- 20 September 2026
- Enrollment
- 32 participants
- Sites
- 1
- Primary outcomes
- Overall Response Rate or Stable Disease
- Sponsor
- Other
- Results posted
- 2026-09-11
- Last update
- 4 November 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Pancreatic cancer is one of the leading causes of cancer deaths in the United States with limited treatment options, especially for those patients with metastatic disease. Combination treatment with cabozantinib and atezolizumab, has demonstrated safety for the treatment of other cancers and has shown promise in preclinical studies utilizing patient derived pancreas organoids. In this study, patients with refractory, metastatic pancreatic cancer will receive combination cabozantinib + atezolizumab and the efficacy of this treatment will be assessed through overall response rate (ORR), disease control rate (DCR), median overall survival (mOS), and median progression free survival (mPFS). Safety and tolerability of combination cabozantinib plus atezolizumab in metastatic pancreatic cancer patients will also be assessed and immune profiling pre- and post-treatment will be explored.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Overall Response Rate or Stable Disease [Participants will be evaluated for response every 3 cycles (each cycle is 21 days) thereafter until disease progression or death from any cause, whichever occurs first (an average of 6 months)]. Number, Proportion of participants (95% Confidence Interval). Overall Response Rate: Cabozantinib 40mg + Atezolizumab 1200mg (n=18): 0.06 (0.00 to 0.27). Stable Disease: Cabozantinib 40mg + Atezolizumab 1200mg (n=18): 0.39 (0.17 to 0.64).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With Adverse Events [Participants will be evaluated for response every 3 cycles (each cycle is 21 days) thereafter until disease progression or death from any cause, whichever occurs first (an average of 6 months)]. Count Of Participants, Participants. Patients with any AE of grade greater than or equal to 3: Cabozantinib 40mg + Atezolizumab 1200mg (n=30): 23. Patients with any serious AE: Cabozantinib 40mg + Atezolizumab 1200mg (n=30): 19.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With Toxicities [Participants will be evaluated for response every 3 cycles (each cycle is 21 days) thereafter until disease progression or death from any cause, whichever occurs first (an average of 6 months)]. Count Of Participants, Participants. Patients with any AE possibly attributed to Cabozantinib: Cabozantinib 40mg + Atezolizumab 1200mg (n=30): 26. Patients with any AE possibly attributed to Atezolizumab: Cabozantinib 40mg + Atezolizumab 1200mg (n=30): 19.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Disease Control Rate [Participants will be evaluated for response every 3 cycles (each cycle is 21 days) thereafter until disease progression or death from any cause, whichever occurs first (an average of 6 months)]. Number, Proportion of participants (95% Confidence Interval). Cabozantinib 40mg + Atezolizumab 1200mg (n=18): 0.44 (0.22 to 0.69).